TY - JOUR
T1 - Survival Impact of Postoperative Skeletal Muscle Loss in Gastric Cancer Patients Who Underwent Gastrectomy
AU - Kuwada, Kazuya
AU - Kikuchi, Satoru
AU - Kuroda, Shinji
AU - Yoshida, Ryuichi
AU - Takagi, Kosei
AU - Noma, Kazuhiro
AU - Nishizaki, Masahiko
AU - Kagawa, Shunsuke
AU - Umeda, Yuzo
AU - Fujiwara, Toshiyoshi
N1 - Funding Information:
We wish to thank all patients who contributed their data for analysis in the present study. This study was supported by the Japanese Gastric Cancer Association (grant number JGCA020).
Publisher Copyright:
© 2023 International Institute of Anticancer Research. All rights reserved.
PY - 2023/1
Y1 - 2023/1
N2 - Background/Aim: It has recently been recognized that preoperative sarcopenia contributes to postoperative complications and overall survival in gastric cancer (GC). However, few studies have investigated the relationship between postoperative skeletal muscle loss (SML) and survival in GC, despite the inevitability of body weight loss after gastrectomy in most GC patients. Herein, we studied the impact of postoperative SML on GC prognosis. Patients and Methods: A total of 370 patients with GC who underwent curative gastrectomy were retrospectively evaluated in this study. Postoperative SML was assessed on computed tomography (CT) images taken before surgery and 1 year after surgery. The impact of postoperative SML on survival was evaluated. Results: Postoperative severe SML was significantly associated with presence of comorbidities, higher tumor stage, higher postoperative complication rate and longer hospital stay. Univariate and multivariate analyses of prognostic factors for overall survival revealed that SML was an independent indicator of poor prognosis, along with age, tumor stage, preoperative sarcopenia, and operation time (hazard ratio, 2.65; 95% confidence interval, 1.68-4.20, p<0.0001). There was a strong association of severe postoperative SML with decreased overall survival in patients with preoperative sarcopenia. Conclusion: To improve the prognosis of GC patients after surgery, it is important to prevent postoperative SML as well as preoperative sarcopenia. Perioperative multimodal interventions including nutritional counseling, oral nutritional supplements, and exercise are required to prevent SML after gastrectomy.
AB - Background/Aim: It has recently been recognized that preoperative sarcopenia contributes to postoperative complications and overall survival in gastric cancer (GC). However, few studies have investigated the relationship between postoperative skeletal muscle loss (SML) and survival in GC, despite the inevitability of body weight loss after gastrectomy in most GC patients. Herein, we studied the impact of postoperative SML on GC prognosis. Patients and Methods: A total of 370 patients with GC who underwent curative gastrectomy were retrospectively evaluated in this study. Postoperative SML was assessed on computed tomography (CT) images taken before surgery and 1 year after surgery. The impact of postoperative SML on survival was evaluated. Results: Postoperative severe SML was significantly associated with presence of comorbidities, higher tumor stage, higher postoperative complication rate and longer hospital stay. Univariate and multivariate analyses of prognostic factors for overall survival revealed that SML was an independent indicator of poor prognosis, along with age, tumor stage, preoperative sarcopenia, and operation time (hazard ratio, 2.65; 95% confidence interval, 1.68-4.20, p<0.0001). There was a strong association of severe postoperative SML with decreased overall survival in patients with preoperative sarcopenia. Conclusion: To improve the prognosis of GC patients after surgery, it is important to prevent postoperative SML as well as preoperative sarcopenia. Perioperative multimodal interventions including nutritional counseling, oral nutritional supplements, and exercise are required to prevent SML after gastrectomy.
KW - gastrectomy
KW - Gastric cancer
KW - sarcopenia
KW - skeletal muscle loss
UR - http://www.scopus.com/inward/record.url?scp=85145275879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145275879&partnerID=8YFLogxK
U2 - 10.21873/anticanres.16153
DO - 10.21873/anticanres.16153
M3 - Article
C2 - 36585161
AN - SCOPUS:85145275879
SN - 0250-7005
VL - 43
SP - 223
EP - 230
JO - Anticancer research
JF - Anticancer research
IS - 1
ER -